Reduced cerebral glucose metabolism in patients at risk for Alzheimer's disease

While significantly reduced glucose metabolism in fronto-temporo-parietal and cingulate cortices has been demonstrated in Alzheimer's disease (AD) compared with controls, cerebral glucose metabolism in patients with mild cognitive impairment who subsequently develop AD is less well-defined. In the present study we measured cerebral glucose metabolism by positron emission tomography (PET) with (18)F-2-fluoro-2-deoxy-D-glucose in 14 patients with aging-associated cognitive decline (AACD), 44 patients with AD, and 14 healthy control subjects at baseline. The AACD patients were clinically followed up, and conversion to AD was determined. Compared with controls, AACD patients had significantly reduced glucose metabolism in the right precuneus, posterior cingulate, right angular gyrus, and bilateral middle temporal cortices, while the respective deficits were more pronounced in AD patients and also involved the frontal cortices. AACD patients who subsequently converted to AD (AACD-converters) showed more extended metabolic changes which also involved the frontal and temporal cortices, right cingulate gyrus, right thalamus, and bilateral precuneus.

[1]  G. Ladurner,et al.  Brain perfusion SPECT in patients with mild cognitive impairment and Alzheimer’s disease: comparison of a semiquantitative and a visual evaluation , 2006, Journal of Neural Transmission.

[2]  A. Barabash,et al.  Regional cerebral blood flow assessed with 99mTc-ECD SPET as a marker of progression of mild cognitive impairment to Alzheimer's disease , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[3]  J. Haxby,et al.  Relations between Neuropsychological and Cerebral Metabolic Asymmetries in Early Alzheimer's Disease , 1985, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[4]  Cheuk Y. Tang,et al.  Patterns of cortical activity and memory performance in Alzheimer’s disease , 2001, Biological Psychiatry.

[5]  H. Feldman,et al.  Apolipoprotein E ε4 genotype as a risk factor for cognitive decline and dementia: data from the Canadian Study of Health and Aging , 2004, Canadian Medical Association Journal.

[6]  Yaakov Stern,et al.  Cognitive reserve: Implications for diagnosis and prevention of Alzheimer’s disease , 2004, Current Neurology and Neuroscience Reports.

[7]  G. Alexander,et al.  Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. , 2001, JAMA.

[8]  Roberta F. White,et al.  The preclinical phase of alzheimer disease: A 22-year prospective study of the Framingham Cohort. , 2000, Archives of neurology.

[9]  M. Essig,et al.  Distribution of cerebral atrophy assessed by magnetic resonance imaging reflects patterns of neuropsychological deficits in Alzheimer's dementia , 2004, Neuroscience Letters.

[10]  P. Scheltens,et al.  Advances in the early detection of Alzheimer's disease , 2004, Nature Reviews Neuroscience.

[11]  Lars-Olof Wahlund,et al.  Cingulate cortex hypoperfusion predicts Alzheimer's disease in mild cognitive impairment , 2002, BMC neurology.

[12]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[13]  M S Buchsbaum,et al.  Temporal and hippocampal metabolic rate during an olfactory memory task assessed by positron emission tomography in patients with dementia of the Alzheimer type and controls. Preliminary studies. , 1991, Archives of general psychiatry.

[14]  J. Touchon,et al.  Classification criteria for mild cognitive impairment , 2001, Neurology.

[15]  Karl J. Friston,et al.  Statistical parametric maps in functional imaging: A general linear approach , 1994 .

[16]  R. Lévy,et al.  Aging-Associated Cognitive Decline , 1994, International Psychogeriatrics.

[17]  J. Baron,et al.  Mild cognitive impairment , 2003, Neurology.

[18]  C. Jack,et al.  Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment , 2004, Journal of internal medicine.

[19]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.

[20]  Hidenao Fukuyama,et al.  Regional Cerebral Blood Flow Abnormalities in Nondemented Patients With Memory Impairment , 2002, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[21]  B L Holman,et al.  Preclinical prediction of Alzheimer's disease using SPECT , 1998, Neurology.

[22]  J R Hodges,et al.  Retrosplenial cortex (BA 29/30) hypometabolism in mild cognitive impairment (prodromal Alzheimer's disease) , 2003, The European journal of neuroscience.

[23]  M. Essig,et al.  Parahippocampal volume deficits in subjects with aging-associated cognitive decline. , 2003, The American journal of psychiatry.

[24]  J Schröder,et al.  Prevalence of mild cognitive impairment in an elderly community sample. , 1998, Journal of neural transmission. Supplementum.

[25]  M. Bobinski,et al.  Prediction of cognitive decline in normal elderly subjects with 2-[18F]fluoro-2-deoxy-d-glucose/positron-emission tomography (FDG/PET) , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[26]  A. Convit,et al.  Hippocampal formation glucose metabolism and volume losses in MCI and AD , 2001, Neurobiology of Aging.

[27]  H. Arai,et al.  [Prediction of progression in patients with mild cognitive impairment using IMP-SPECT]. , 2000, Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics.

[28]  A. Drzezga,et al.  Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[29]  L. Schad,et al.  Progressive medial temporal lobe changes in Alzheimer's disease revealed by quantitative MRI: potential use for monitoring of drug‐related changes , 2002 .

[30]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.

[31]  M. Essig,et al.  Cerebrospinal fluid tau levels in Alzheimer's disease are elevated when compared with vascular dementia but do not correlate with measures of cerebral atrophy , 2003, Psychiatry Research.

[32]  J. Morris.  The Clinical Dementia Rating (CDR) , 1993, Neurology.

[33]  Peter Schönknecht,et al.  Prevalence and natural course of aging-associated cognitive decline in a population-based sample of young-old subjects. , 2005, The American journal of psychiatry.

[34]  Erminia Mariani,et al.  Conversion of Mild Cognitive Impairment to Dementia: Predictive Role of Mild Cognitive Impairment Subtypes and Vascular Risk Factors , 2005, Dementia and Geriatric Cognitive Disorders.

[35]  J. Talairach,et al.  Co-Planar Stereotaxic Atlas of the Human Brain: 3-Dimensional Proportional System: An Approach to Cerebral Imaging , 1988 .

[36]  et al.,et al.  Discrimination between Alzheimer Dementia and Controls by Automated Analysis of Multicenter FDG PET , 2002, NeuroImage.

[37]  O Almkvist,et al.  Impaired cerebral glucose metabolism and cognitive functioning predict deterioration in mild cognitive impairment , 2001, Neuroreport.

[38]  J Marshall,et al.  Cerebral blood flow in dementia. , 1975, Archives of neurology.